Stockscreener 앱 받기
48.12
5.25%
2.40
시장 영업 전:
47.92
-0.20
-0.42%
전일 마감가:
$45.72
열려 있는:
$46.04
하루 거래량:
4.77M
Relative Volume:
0.61
시가총액:
$19.09B
수익:
$2.23B
순이익/손실:
$-3.19B
주가수익비율:
-5.907
EPS:
-8.1462
순현금흐름:
$-1.60B
1주 성능:
-4.56%
1개월 성능:
-11.85%
6개월 성능:
+115.21%
1년 성능:
+71.92%
1일 변동 폭
$45.95
$48.77
1주일 범위
$45.62
$50.80
52주 변동 폭
$22.28
$59.55
모더나 Stock (MRNA) Company Profile
명칭
Moderna Inc
전화
(617) 714-6500
주소
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
48.12 | 19.09B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
430.44 | 110.81B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.76 | 66.02B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
804.25 | 48.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.48 | 38.22B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
308.74 | 30.41B | 5.76B | 514.49M | 1.10B | 4.4813 |
모더나 Stock (MRNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 재개 | Barclays | Equal Weight |
| 2026-01-07 | 재개 | UBS | Neutral |
| 2025-12-12 | 개시 | Jefferies | Hold |
| 2025-03-13 | 개시 | Citigroup | Neutral |
| 2025-02-18 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-01-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-12-18 | 다운그레이드 | Argus | Buy → Hold |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-19 | 개시 | Berenberg | Hold |
| 2024-11-18 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-11-15 | 개시 | Wolfe Research | Underperform |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-09-13 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-09-13 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-09-13 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-08-28 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-08-07 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-08-05 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2024-01-02 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-11-29 | 개시 | Canaccord Genuity | Hold |
| 2023-11-03 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2023-11-02 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2023-08-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-07-24 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-06-26 | 업그레이드 | UBS | Neutral → Buy |
| 2023-04-26 | 개시 | Guggenheim | Neutral |
| 2023-03-13 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | 개시 | RBC Capital Mkts | Outperform |
| 2023-02-24 | 다운그레이드 | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-12-14 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2022-02-01 | 업그레이드 | Redburn | Sell → Neutral |
| 2022-01-26 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2022-01-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-01-21 | 개시 | UBS | Neutral |
| 2021-12-07 | 개시 | Cowen | Market Perform |
| 2021-11-09 | 개시 | Wolfe Research | Outperform |
| 2021-10-22 | 개시 | Deutsche Bank | Sell |
| 2021-10-15 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-08-06 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | 재확인 | Jefferies | Hold |
| 2021-02-01 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-12-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-12-16 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | 다운그레이드 | Needham | Buy → Hold |
| 2020-11-23 | 개시 | Wells Fargo | Equal Weight |
| 2020-11-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | 개시 | SVB Leerink | Mkt Perform |
| 2020-07-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-07-13 | 개시 | Jefferies | Buy |
| 2020-06-30 | 개시 | Argus | Buy |
| 2020-06-08 | 개시 | Barclays | Overweight |
| 2020-04-30 | 개시 | BMO Capital Markets | Outperform |
| 2020-03-05 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | 재개 | BofA/Merrill | Buy |
| 2019-10-25 | 개시 | ROTH Capital | Buy |
| 2019-04-05 | 개시 | Chardan Capital Markets | Buy |
모두보기
모더나 주식(MRNA)의 최신 뉴스
Moderna, Inc. Trade Ideas — LSX:A2N9D9 - TradingView
Moderna stock (US60770K1034): Hantavirus headlines, Q1 revenue beat and lingering volatility - AD HOC NEWS
ROIV Stock Nears Record High –Retail Traders See Breakout After Surprise Earnings Beat - Stocktwits
Moderna’s stock rides hantavirus fears as spotlight returns to infectious disease platform - BioSpace
Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain - TradingView
ROIV: Strong clinical progress and a $2.25B Moderna settlement drive robust financial position - TradingView
CHINA SHOTO : 15000 Leverage Shares 3x Long Moderna (MRNA) ETP Securities - marketscreener.com
Moderna Inc. stock (US60770K1034): FDA path, vaccine sales and pipeline updates in focus - AD HOC NEWS
2 Healthcare Stocks Worth Investigating and 1 Facing Headwinds - The Globe and Mail
Moderna’s SWOT analysis: biotech stock faces profitability test - Investing.com
Invesco S&P 500 Equal Weight Income Advantage ETF's Moderna Inc(MRNA) Holding History - GuruFocus
Transcript : Moderna, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2026, May-19-2026 10 - marketscreener.com
MRNA: International partnerships and new vaccines fuel growth amid strong clinical and regulatory progress - TradingView
Moderna Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Moderna stock (US60770K1034): Insider sale adds to a volatile setup - AD HOC NEWS
Moderna president Stephen Hoge sells $2.58m in shares - Investing.com
Moderna (MRNA) president sells 53,336 shares after option exercises - Stock Titan
HHS rescinds vaccine panel charter citing 'administrative error' - Seeking Alpha
Moderna's revenues see strong international momentum in Q1 earnings - MSN
Moderna Inc. stock (US60770K1034): Shares slip as post-COVID reset keeps volatility high - AD HOC NEWS
Moderna, Inc. (MRNA): Navigating a Complex Landscape with Potential Growth in Biotechnology - DirectorsTalk Interviews
Moderna stock (US60770K1034): Shares slide as COVID-era sales reset remains in focus - AD HOC NEWS
Moderna Inc stock (US60770K1079): FDA review, vaccine pipeline and cash burn stay in focus - AD HOC NEWS
Moderna | History, Innovation, Challenges, & Facts - Britannica
Assessing Moderna (MRNA) Valuation After Flu Vaccine Trial Success And Hantavirus Research Attention - Yahoo Finance
Moderna, Inc. - TradingView
VIRGINIA RETIREMENT SYSTEMS ET Al Purchases 23,550 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna Inc stock (US60770K1079): pipeline momentum and volatile share price keep investors on edge - AD HOC NEWS
MRNA Stock Quote Price and Forecast - CNN
Hantavirus: Is there a risk of another pandemic? - Investing.com
Moderna Recognized by TIME as One of the World's Most Impactful Companies - ACCESS Newswire
Moderna, Inc. (MRNA): Stock Analysis | Is It A Buy? | Feb 2025 | Trending Investment Insights (a6zSgQ1FJr) - fathomjournal.org
Moderna stock (US60770K1034): pipeline hopes meet volatile share price - AD HOC NEWS
Moderna (MRNA) Rule 144 notice: 53,336 shares proposed via Fidelity on 05/15/2026 - Stock Titan
Moderna stock (US60770K1034): focus on vaccine pipeline after latest earnings - AD HOC NEWS
Moderna Inc (MRNA:NSD) Sell The Strength As Stock Jumps On Trial Results (E66AVda6nQ) - fathomjournal.org
Moderna shares jump as it reveals it has been researching vaccines against hantaviruses - AOL.com
Moderna stock (US60770K1079): Shares up 71% YTD amid biotech volatility - AD HOC NEWS
Salesforce (CRM), Moderna Partner to Unify Global Operations via Agentforce Life Sciences - Yahoo Finance
Moderna stock (US60770K1034): Q1 2026 net income swings to $169.7M profit - AD HOC NEWS
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally - The Motley Fool
Moderna stock (US60770K1034): Ranked #1 on TIME's 2026 Most Impactful Companies - AD HOC NEWS
Still ‘many steps to do’ in creating a hantavirus vaccine, experts say - Global News
Stock market today: S&P 500, Dow futures fall as Trump rejects 'totally unacceptable' Iran peace proposal—Micron Technologies, Moderna in focus - MSN
Moderna stock (US60770K1034): Gains 0.74% to $53.27 on May 12 - AD HOC NEWS
Arbutus Biopharma Q1 revenue surges on Moderna settlement - TradingView
Moderna settlement drives Arbutus (NASDAQ: ABUS) to $169.7M Q1 profit - Stock Titan
Moderna Is a Money-Losing Vaccine Maker. It’s Also the Ultimate Stock Hedge. - Barron's
Whitefort Capital Management, LP's Moderna Inc(MRNA) Holding History - GuruFocus
Money-Losing Moderna Is a Pandemic Hedge. What to Do With the Stock Now. - Barron's
Moderna (MRNA) Shares Skyrocket, What You Need To Know - Yahoo Finance
모더나 (MRNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.93%
자본화:
|
볼륨(24시간):